Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15067325 | 0.82 | ALDH1A1 (0.43) | ALDH1A1USP2GAAPKMHPGD | |
| SCHEMBL11410565 | 0.80 | ALDH1A1 (0.42) | ALDH1A1USP2GAAPKMHPGD | |
| SCHEMBL20299156 | 0.78 | PNMT (0.32) | ALDH1A1USP2GAAPKMHPGD | |
| SCHEMBL11619605 | 0.78 | ALDH1A1 (0.41) | ALDH1A1USP2GAAPKMHPGD | |
| SCHEMBL530329 | 0.76 | ALDH1A1 (0.39) | ALDH1A1USP2GAAPKMHPGD | |
| SCHEMBL7775689 | 0.76 | RORC (0.38) | ALDH1A1HPGDALOX15HSD17B10RORC | |
| SCHEMBL7482706 | 0.76 | ABCB11 (0.37) | ALDH1A1GAAHPGD | |
| SCHEMBL145537 | 0.74 | ALDH1A1 (0.38) | ALDH1A1USP2GAAPKMHPGD | |
| SCHEMBL11618627 | 0.73 | HDAC4 (0.41) | ALDH1A1USP2GAAPKMHPGD | |
| SCHEMBL699057 | 0.72 | RORC (0.32) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-07-04 | — | — | US | claimed |
| WO-2023196594-A2 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-12 | — | — | WO | claimed |
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-07-04 | — | — | US | disclosed |
| WO-2023196594-A2 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196602-A1 | INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-112384593-A | Photostable cyano-substituted boron dipyrromethene dyes as green emitters for display and lighting applications | 巴斯夫欧洲公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-2632929-A1 | N-HETEROCYCLIC CARBENE COMPLEXES, THEIR PREPARATION AND USE | BASF SE (DE) | 2013-09-04 | — | — | EP | disclosed |
| CN-103180332-A | N-heterocyclic carbene complexes, preparation and application thereof | BASF SE | 2013-06-26 | — | — | CN | disclosed |
| CN-101035788-B | Process for the preparation of halogenated rylen-carboximides by halogenation of rylene-carboximides with elemental halogen in a two-phase mixture comprising an organic solvent and water | BASF AG | 2013-01-23 | — | — | CN | disclosed |
| WO-2012056419-A1 | N-HETEROCYCLIC CARBENE COMPLEXES, THEIR PREPARATION AND USE | BASF SE (DE) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108819-A1 | N-Heterocyclic Carbene Complexes, Their Preparation And Use | BASF SE (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20060257706-A1 | POLYMER ELECTROLYTE COMPOSITION AND FUEL CELL | HIDAKA YASUAKI | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | FABP7, FFAR1, FABP1 | ALDH1A1 4484/4885USP2 4831/4885GAA 1861/4885 |
| US-20120108819-A1 | N-Heterocyclic Carbene Complexes, Their Preparation And Use | CYCS, CYC1, CBR1 | ALDH1A1 1797/4885USP2 2866/4885GAA 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.